Why HubSpot Shares Are Trading Higher Today

HubSpot, Inc. (NYSE: HUBS) shares are trading about 6.5% higher at $280.83 per share Thursday afternoon after the company reported better-than-expected third-quarter financial results. The company also issued fourth-quarter and full-year 2022 guidance above estimates.

HubSpot, Inc. (NYSE:HUBS) shares are trading about 6.5% higher at $280.83 per share Thursday afternoon after the company reported better-than-expected third-quarter financial results. The company also issued fourth-quarter and full-year 2022 guidance above estimates.

The company reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.51 and reported quarterly sales of $443.96 million which beat the analyst consensus estimate of $425.38 million.

HubSpot expects fourth-quarter earnings per share in the range of $0.82 and $0.84 versus the $0.79 estimate and expects sales in the range of $444 million and $446 million versus the $449.54 million estimate.

The company also expects full-year 2022 earnings per share in the range of $2.48 and $2.50 versus the $2.27 estimate and expects sales in the range of $1.705 billion and $1.707 billion versus the $1.69 billion estimate.

According to data from Benzinga Pro, HUBS has a 52-week high of $866.00 and a 52-week low of $245.03.

Total
0
Shares
Related Posts
Read More

Earnings Preview: Evoke Pharma

Evoke Pharma (NASDAQ:EVOK) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that Evoke Pharma will report an earnings per share (EPS) of $-0.66.

EVOK

Read More

Palvella Therapeutics And Ligand Pharmaceuticals Expand Strategic Partnership To Accelerate Phase 3 Development Of QTORIN Rapamycin For Microcystic Lymphatic Malformations And Additional High Unmet Need Clinical Indications; Palvella Received $5M Payme…

Palvella Received $5 Million Upfront Payment QTORIN™ rapamycin has Potential to be First FDA Approved Therapy and Standard of Care in the U.S. for an Estimated more than 30,000 Diagnosed Patients with

LGND